Luke Russell
Executive VP Vyriad
Luke Russell, Ph.D., is Executive Vice President at Vyriad, a clinical-stage biotech developing targeted genetic and oncolytic virus therapies. He drives business development, strategic alliances and operations to advance Vyriad’s portfolio and partnerships in in-vivo and immuno-oncology modalities. Luke holds a Ph.D. in Neuroscience and an MBA in Finance and Strategy, and has expertise spanning research analysis, competitive landscape insight, and translational biotech initiatives.
Seminars
Tuesday 15th September 2026
Panel Discussion: Investigating the Evolution of In Vivo Therapies to Accelerate Innovations
9:30 am
- Discussing the rapid progression of in vivo therapies, considering the impact on COGs and patient outcomes
- Highlighting in vivo innovations to develop more effective, scalable, and accessible therapies
- Evaluating what’s next for in vivo therapies to understand anticipated clinical progress, expanding disease indications and projected advancements for strategic planning
Tuesday 15th September 2026
Developing High-Quality Lentiviral Vectors to Enhance Reliable Delivery & Reduce Cost
2:00 pm
- Examining lentiviral delivery platforms to understand current industry benchmarks and opportunities for innovation
- Optimizing vector design and production strategies to enhance durable CAR expression
- Evaluating scalability and manufacturing readiness of lentiviral vectors to support sustainable in vivo clinical and commercial deployment
